Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Profit After Tax: 2017-2025

Historic Profit After Tax for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $8.8 million.

  • Puma Biotechnology's Profit After Tax fell 56.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 59.31%. This contributed to the annual value of $30.3 million for FY2024, which is 40.34% up from last year.
  • As of Q3 2025, Puma Biotechnology's Profit After Tax stood at $8.8 million, which was up 51.05% from $5.9 million recorded in Q2 2025.
  • Puma Biotechnology's Profit After Tax's 5-year high stood at $20.3 million during Q3 2024, with a 5-year trough of -$44.7 million in Q3 2021.
  • Over the past 3 years, Puma Biotechnology's median Profit After Tax value was $5.8 million (recorded in 2023), while the average stood at $6.3 million.
  • In the last 5 years, Puma Biotechnology's Profit After Tax surged by 1,710.00% in 2023 and then plummeted by 443.68% in 2024.
  • Over the past 5 years, Puma Biotechnology's Profit After Tax (Quarterly) stood at $4.2 million in 2021, then tumbled by 232.72% to -$5.6 million in 2022, then spiked by 318.84% to $12.3 million in 2023, then skyrocketed by 57.54% to $19.3 million in 2024, then tumbled by 56.47% to $8.8 million in 2025.
  • Its Profit After Tax stands at $8.8 million for Q3 2025, versus $5.9 million for Q2 2025 and $3.0 million for Q1 2025.